RxDoctor Payments Data

David Wong, MD

Interventional Cardiology · Humble, TXNPI 1609210897

Payments from drug & device makers

$62,194in general payments, 2019–2025

Across 432 payments — averaging $143.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$27K
  • Inari Medical, Inc.$9K
  • Shockwave Medical, Inc$8K
  • Abbott$7K
  • Boston Scientific$5K
  • Abiomed$1K
  • plus $6K from 36 others

What the payments were for

  • Consulting fees$28,09245%
  • Speaking & faculty fees$6,40010%
  • Grants$1230%
  • Travel & lodging$8,01213%
  • Food & beverage$19,39731%
  • Education$1690%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,194 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$132,512
Medicare patients
486
Services billed
1,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$70,191
XareltoRivaroxaban38$47,016
BrilintaTicagrelor45$38,318
EntrestoSacubitril/Valsartan20$18,957
Praluent PenAlirocumab24$16,284
FarxigaDapagliflozin Propanediol15$10,365
Repatha SureclickEvolocumab13$7,107
Prasugrel Hcl20$4,531
Rosuvastatin Calcium185$2,047
ClopidogrelClopidogrel Bisulfate152$1,349
Metoprolol Succinate74$927
Atorvastatin Calcium111$737
Nifedipine ErNifedipine32$724
Ezetimibe36$690
Amlodipine Besylate99$603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$54$70,19155 claims
AstraZenecaBrilinta, Farxiga$140$48,68360 claims
Johnson & JohnsonXarelto$138$47,01638 claims
NovartisEntresto$191$18,95720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Humble

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →